Scholarlink

<p>The management of brain metastases (BrM) remains a major clinical challenge due to limited drug delivery across the blood-brain barrier (BBB) and the need for simultaneous CNS and systemic disease management, often with competing therapeutic strategies. Antibody-drug conjugates (ADCs) are a promising class of drugs that offers precision therapy by combining the specificity of monoclonal antibodies with potent chemotherapeutics for targeted tumor delivery. This review explores the current landscape of ADCs in BrMs, challenges in BBB penetration, and CNS-specific toxicities, including interactions with radiotherapy and the risk of radiation necrosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges

  • 期刊论文

  • 发表日期：

    2025年6月5日

查看全文
  • Stephanie M. Robert,
  • Allison Toth,
  • Sapir Lev,
  • Stephen G. Bowden,
  • Yao Yu,
  • Brandon S. Imber,
  • Adrienne Boire,
  • Joshua Z. Drago,
  • Shanu Modi,
  • Nelson S. Moss

摘要

The management of brain metastases (BrM) remains a major clinical challenge due to limited drug delivery across the blood-brain barrier (BBB) and the need for simultaneous CNS and systemic disease management, often with competing therapeutic strategies. Antibody-drug conjugates (ADCs) are a promising class of drugs that offers precision therapy by combining the specificity of monoclonal antibodies with potent chemotherapeutics for targeted tumor delivery. This review explores the current landscape of ADCs in BrMs, challenges in BBB penetration, and CNS-specific toxicities, including interactions with radiotherapy and the risk of radiation necrosis.